Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Terufumi, Seto, Takashi, Nishio, Makoto, Goto, Koichi, Yamamoto, Noboru, Okamoto, Isamu, Tao, Liang, Yu, Wei, Khaznadar, Tarik, Tajima, Kosei, Shibata, Masahiko, Seki, Akihiro, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808045/
https://www.ncbi.nlm.nih.gov/pubmed/29043496
http://dx.doi.org/10.1007/s40264-017-0596-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808045/
https://www.ncbi.nlm.nih.gov/pubmed/29043496
http://dx.doi.org/10.1007/s40264-017-0596-0

Ejemplares similares